skip to navigation skip to content

Business Weekly: Genomic signatures matched to best drugs for rare disease sufferers


The startup Healx has developed a novel treatment allocation method allowing prediction of drug response, writes Kate Sweeney in Business Weekly. “We believe the impact could be enormous, including for the healthcare system,” said Tim Guilliams, founder of Healx. The start-up is supported by the Accelerate Cambridge programme at Cambridge Judge Business School.


Read the full article []